Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul-Aug;24(4):320-326.
doi: 10.5863/1551-6776-24.4.320.

Effectiveness of Levetiracetam as a First-Line Anticonvulsant for Neonatal Seizures

Alexander M Kreimer, Robert A Littrell, Julia B Gibson, Noelle R Leung

Effectiveness of Levetiracetam as a First-Line Anticonvulsant for Neonatal Seizures

Alexander M Kreimer et al. J Pediatr Pharmacol Ther. 2019 Jul-Aug.

Abstract

Objective: Optimal treatment for neonatal seizures remains unclear, and management among US hospitals is highly varied. The purpose of this study was to evaluate the effectiveness of levetiracetam as a first-line treatment for seizures in a neonatal population.

Methods: A single-center, retrospective review of neonates at a tertiary medical center who received levetiracetam as a first-line agent after benzodiazepines for seizure control between 2015 and 2017 was conducted. Chart review was completed to analyze patient and treatment characteristics. The primary outcome was seizure control, defined as clinical seizure cessation and video electroencephalogram resolution, with no new seizures documented prior to discharge.

Results: A total of 36 patients met inclusion criteria. Seventeen patients (47%) had seizure control after intravenous levetiracetam as monotherapy. Eighteen patients required a second anticonvulsant, of which 13 (72%) had seizure control. In total, 30 patients (83%) had seizure control with levetiracetam monotherapy or combination therapy of levetiracetam plus fosphenytoin or phenobarbital.

Conclusions: Levetiracetam monotherapy provided seizure control in about 50% of the patients reviewed. Overall, seizure control was observed in 83% of the study population that received either levetiracetam monotherapy or combination therapy of levetiracetam plus fosphenytoin or phenobarbital as a second-line agent. Further studies are warranted to directly compare historical therapies with levetiracetam for neonatal seizure control.

Keywords: anticonvulsant; levetiracetam; monotherapy; neonatal, seizure.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors declare no conflicts or financial interest in any product or service mentioned in the manuscript, including grants, equipment, medications, employment, gifts, and honoraria. Dr Alexander Kreimer had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

References

    1. Geetha S, Sarasam S, Iype M et al. Comparison of clinical and etiologic profile of neonatal seizures over a decade—a hospital based prospective study. J Med Sci Clin Res. 2017;5:19495–19501.
    1. Ronen G, Buckley D, Penney S et al. Long-term prognosis in children with neonatal seizures: a population-based study. Neurology. 2007;69:1816–1822. - PubMed
    1. Glass H, Kan J, Bonifacio S et al. Neonatal seizures: treatment practices among term and preterm. Pediatr Neurol. 2012;46(2):111–115. - PMC - PubMed
    1. Silverstein F, Ferriero D. Off-label use of antiepileptic drugs for the treatment of neonatal seizures. Pediatr Neurol. 2008;39:77–79. - PubMed
    1. World Health Organization Guidelines on neonatal seizures. 2011:1–100. http://www.who.int/mental_health/publications/guidelines_neonatal_seizur... Accessed June 24, 2018. - PubMed

LinkOut - more resources